The U.S. Food and Drug Administration (FDA) is facing growing attention over how it evaluates Rare Disease Therapies in 2026. Discussions around FDA Advisory Committees (AdComms) and patient-focused decision-making highlight a broader regulatory transformation that may reshape how pharmaceutical companies
